Related Experiment Video
Updated: Mar 28, 2026
Inducible and Reversible Dominant-negative DN Protein Inhibition
Published on: January 7, 2019
LOX1 inhibition with small molecules
Chrysoula Gousiadou1, Irene Kouskoumvekaki2
1Department of Chemistry, Technical University of Denmark, DK-2800 Lyngby, Denmark.
Abstract:
Lipoxygenases (LOXs) are nonheme, iron-containing dioxygenases that catalyze the dioxygenation of polyunsaturated fatty acids and are widely distributed among plant and animal species. Human LOXs, now identified as key enzymes in the pathogenesis of major disorders, have increasingly drawn the attention as targets and great effort has been made for the discovery and design of suitable inhibitors, to which end both pharmacological and computational methods have been employed. In the present work, using pharmacophore modeling and docking, we attempt to elucidate the inhibition of LOX1 with a new inhibitor, albidoside, an iridoid glucoside isolated from plants of the Scutellaria genus. Through a pharmacophore approach, complementarities between the ligand and the binding site are explored and a plausible mode of binding with the protein is suggested for albidoside.
Insights
Researchers explored how albidoside, a plant-derived compound, inhibits lipoxygenase 1 (LOX1). Computational methods suggest a specific binding mode, offering insights for developing new LOX1 inhibitors for disease treatment.
Area of Science:
- Biochemistry
- Pharmacology
- Computational Chemistry
Background:
- Lipoxygenases (LOXs) are iron-containing enzymes crucial in polyunsaturated fatty acid metabolism.
- Human LOXs are implicated in the pathogenesis of various diseases, making them important therapeutic targets.
- Developing effective LOX inhibitors requires understanding their interaction with the enzyme.
Purpose of the Study:
- To elucidate the inhibition mechanism of lipoxygenase 1 (LOX1) by albidoside, an iridoid glucoside.
- To explore the binding interactions between albidoside and the LOX1 active site using computational approaches.
- To provide a basis for the rational design of novel LOX1 inhibitors.
Main Methods:
- Pharmacophore modeling to identify key interactions between the inhibitor and the enzyme's binding site.
- Molecular docking simulations to predict the binding pose and affinity of albidoside within the LOX1 active site.
- Analysis of ligand-protein complementarities to understand the inhibition mechanism.
Main Results:
- Pharmacophore modeling revealed specific interaction patterns essential for albidoside's inhibitory activity.
- Docking studies suggested a plausible binding mode for albidoside within the LOX1 active site.
- The study identified key amino acid residues involved in the binding interaction.
Conclusions:
- Albidoside effectively inhibits LOX1 through specific binding interactions.
- Computational methods provide valuable insights into the mechanism of LOX1 inhibition by iridoid glucosides.
- Findings support the potential of albidoside and similar compounds as therapeutic agents targeting LOX1-mediated diseases.
Related Concept Videos
01:30Enzyme Inhibition
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...